Ongoing Clinical Trials

Study of Ziprasidone (Geodon) As an Add-onTtreatment for Depression
While most all patients with schizophrenia get some symptom relief from medication, up to 40% do not get complete relief from the symptoms of schizophrenia despite taking medications as prescribed by their doctor.
Read more here...

Schizophrenia/Schizoaffective Disorder with Inadequate Response toTtreatment
Researchers are conducting a 6-month study of long-acting risperidone (Consta) to see if using higher doses will provide relief of symptoms that have not gone away with usual doses of antipsychotics.
Read more here...

Studies Closed for Accrual:

Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) and Depression
Researchers at USC School of Medicine are conducting an 8-week study evaluating the effectiveness of escitalopram (Lexapro®) in the treatment of Major Depression in ALS and MS. Escitalopram is a FDA approved medication for Major Depressive Disorder.
Read more here...

Autism
Autism is one of the fastest growing developmental disorders that typically appears during the first three years of life and affects a person’s ability to communicate and interact with others. Autism is a spectrum disorder affecting communication and interpersonal skills to varying degrees. Autism affects nearly 1 in every 150 children, has no known cause and is a life-long disorder. Very few medications are approved to help manage some of the more severe problems children with autism often experience.
Read more here ...

Bipolar Disorder
Researchers are conducting a study to evaluate the effectiveness of aripiprazole (Abilify®) when used in combination with either lithium or valproate for the treatment of mania in Bipolar I Disorder.  It is possible for participation to last up to 58 weeks, including a 4-week Screening/Washout Period, a 2-week Lithium/Valproate Evaluation Period, a 6-Week Double-Blind Treatment Period and a 46-Week Open-Label Treatment Period.
Read more here...

Depression
Researchers are conducting a 14-week study of aripiprazole (Abilify®) to evaluate its safety and effectiveness as an add-on treatment for depression.
Read more here...

Depression
Researchers are conducting a 16-week study of antidepressants and corticotropin releasing factor (CRF), a chemical which occurs naturally in the body. Researchers will study what role CRF plays in treating symptoms of depression.
Read more here...

Major Depression with Inadequate Response to Treatment
Is your antidepressant not working for you? In the next few weeks we will be recruiting for a new study to explore an investigational medication for depression to see if it may help to improve depression when taken with an approved antidepressant.
Read more here ...

Schizophrenia/Schizoaffective Disorder and Weight Gain
Some people gain weight while taking medications called antipsychotics which treat the symptoms of schizophrenia. Weight gain can lead to obesity which places a person at higher risk for diabetes and heart disease. Researchers want to better understand the issues behind medications for schizophrenia and weight gain.
Read more here...

Schizophrenia/Schizoaffective Disorder and Marijuana Use
Researchers are conducting a 3-month study to study the impact of clozapine on marijuana use to determine if medication can help people with schizophrenia reduce marijuana use and improve their mental health.
Read more here...

Schizophrenia/Schizoaffective Disorder and Alcohol Use
Researchers are conducting a 6-month study comparing two types of risperidone (Risperdal®) to determine if medication can help people with schizophrenia reduce drinking.
Read more here...